Category: clinical study retractions

A journal has retracted a meta-analysis on Covid-19 after concerned readers complained about the quality — or lack thereof — of the study. 

The article, “A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients,” appeared in Therapeutic Advances in Chronic Disease, a SAGE title. 

According to the retraction notice: 

A group of researchers in Egypt have lost a second paper on possible treatments for Covid-19 after questions were raised about the legitimacy of their trial findings — and additional retractions might be coming soon.

As we reported in September, the group lost an article in Scientific Reports about a purported trial comparing  favipiravir and hydroxychloroquine to treat the infection. 

That move followed an expression of concern, issued in early August, for a paper in the Archives of Virology by Dabbous and his colleagues about favipiravir, titled “Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.” 

The journal has now retracted the article: 

A group of neurosurgery researchers in Tunisia have lost a 2021 case study on childhood meningitis after the editors discovered evidence of plagiarism and image manipulation. 

The article, “A case of meningitis due to Achromobacter xylosoxidans in a child with a polymalformative syndrome: a case report,” appeared in the Pan African Medical Journal and was written by a team lead by Mehdi Borni, of the Department of Neurosurgery at University Hospital Center Habib Bourguiba, in Sfax.

According to the notice: 

A Wisconsin physician who has been pushing unproven treatments for Covid-19 has lost a paper on a hospital protocol his group says radically reduced deaths from the infection after one of the facilities cited in the study said the data were incorrect.  

Pierre Kory, whose titles have included medical director of the Trauma and Life Support Center Critical Care Service and chief associate professor of medicine at the University of Wisconsin School of Medicine and Public Health, in Madison, has become a key figure in the controversy over the use of ivermectin — the deworming agent that proponents insist can treat Covid-19 despite a lack of evidence that it does.

In late December 2020, Kory — who rails on Twitter about unfair and incompetent journals — and another ivermectin advocate, Paul Marik, of Eastern Virginia Medical School in Norfolk, and several other authors published a paper in the Journal of Intensive Care Medicine on a group they’d created called the Front-Line COVID-19 Critical Care Alliance. Per the article: 

The authors of a study purportedly showing that ivermectin could treat patients with  SARS-CoV-2 have retracted their paper after acknowledging that their data were garbled. 

The paper, “Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon,” appeared in the journal Viruses in May. According to the abstract: 

A virology journal has retracted and replaced a 2021 article on mosquito-borne infections in Africa after one of the authors identified errors in the publication — an episode that has prompted a change in practice at the journal to avoid similar issues in the future. 

The article, “Mosquito-borne arboviruses in Uganda: history, transmission and burden,” was written by a group in the United Kingdom and Uganda and appeared in the Journal of General Virology last June. 

According to the retraction notice: 

The authors of a study comparing hydroxychloroquine and the antiviral agent favipiravir as treatments for COVID-19 have lost the paper after post-publication peer review determined that the data did not support the conclusions. 

“Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial” appeared in March in Scientific Reports, a Nature title. The authors, from institutions in Egypt, reported that: